ArticleOncotarget2021

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer.

Sasagu Kurozumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.